• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Autoimmune polyglandular syndromes
 

Autoimmune polyglandular syndromes

on

  • 114 views

Autoimmune polyglandular syndromes autoimmune polyendocrine syndrome

Autoimmune polyglandular syndromes autoimmune polyendocrine syndrome
APS-1,APS-2

Statistics

Views

Total Views
114
Views on SlideShare
114
Embed Views
0

Actions

Likes
1
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Autoimmune polyglandular syndromes Autoimmune polyglandular syndromes Presentation Transcript

    • APSDr.Yassin M Al-saleh Dr.Mohammad Algufiliy
    • ‫الرحيم‬ ‫الرحمن‬ ‫هللا‬ ‫بسم‬ (‫إال‬ ‫العلم‬ ‫من‬ ‫أوتيتم‬ ‫وما‬ ‫قليال‬)
    • OBJIECTIVES • Case. • Introduction. • Classification. • APS-1 • Pathogenesis. • Presentation. • Management. • APS-2. • Other APS.
    • Case • rafal is 3 year old girl referred from MCH- Qasseem with hypoparathyrodisim. • Where she presented with generalized convulsion . • found to have low ca 1.1 ,high phosporus 3.7 ,low PTH 0.27 • Also patient having malabsorption in regular follow up with GIT clinic . • Family history: consangious marriage. • father have DM and hemihypertorphy. • One cousin with APS-1.
    • case • On exam: • Wt:5th. Ht: 5th. Poor dentation,Hemihypertrophy. • Screeing done for her: • LFT:WNL . • U/E:WNL. • HbA1c:WNL. • ACTH,cortisol:WNL • TFT:WNL • Islet cell, throid,adrenal antibodies :negative. • AIRE gene mutation :positive.
    • synonyms • autoimmune polyendorine syndromes (APS). • autoimmune polyglandular syndromes (APS). • polyglandular autoimmune syndromes (PAS)/ (PGAS). • autoimmune polyendocrinopathy. • polyglandular failure syndromes.
    • introduction • Definition: • are a heterogeneous group of uncommon diseases characterized by autoimmune activity against more than one organ (endocrine OR non-endocrine). • The autoimmune polyglandular syndromes result from a loss of tolerance to self-antigens. Maurizio Cutolo. Autoimmune polyendocrine syndromes. Autoimmunity Reviews 13 (2014) 85–89
    • classification
    • Autoimmune polyendocrine syndrome type 1 (APS-1) • This condition is also termed as APECED autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. • Also called Whitaker's syndrome • Due to a monogenetic mutation • Males and females are equally affected Dtsch Med Wochenschr. 2013 Feb;138(7):319-26; quiz 327-8. doi: 10.1055/s- 0032-1327355. Epub 2013 Feb 7.[Autoimmune polyglandular syndromes]. introduction
    • epidemiology • the disease is not common • an incidence of 1:100 000 . • The highest prevalence have been found in certain populations with high degree of consanguinity . • in Iranian Jews (1:9,000) • in Finland (1:14,000) • in Sardinia (1:25,000) • In Norway (1:80,000) George J Kahaly. Polyglandular autoimmune syndromes. European Journal of Endocrinology (2009) 161 11–20 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • pathogenesis • an autosomal recessive disease. • linked to mutation of the AIRE gene (Autoimmune Regulator gene) on chromosome 21q22.3. Autoimmune polyendocrine syndrome type 1 (APS-1) MichelsAW: Autoimmune polyglandular syndromes.nat rev endocrinology. 2010 May;6(5):270-7. doi: 10.1038/nrendo.2010.40. Epub 2010 Mar 23.
    • pathogenesis • AIRE gene is expressed mainly in the thymus. • Expressed in medullary thymic epithelial cells (mTECS) . • But also in lymph nodes, liver, pancreas, adrenal cortex, and testes. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • pathogenesis • More than 70 different mutations in the AIRE gene have now been reported. • mutations can be confirmed in more than 95% of patients with clinical diagnoses of APS I Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Pathogenesis North American, British, and Norwegian Iranian Jews Sardinian Finland Autoimmune polyendocrine syndrome type 1 (APS-1)
    • pathogenesis • several hypotheses have been put forward to explain how an individual can lose its tolerance against self antigens. • the release of sequestered antigens. • environment-induced alterations of host membrane proteins. • crossreactivity between environmental agents and host antigens. • A defect in the cells regulating the immune response Corrado Betterle, Renato Zanchetta: Update on autoimmune polyendocrine syndromes (APS) .ACTA BIO MEDICA 2003; 74; 9-33 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • pathogenesis • Also hypothesis is that organs deriving from a same germ layer can express common germ-layer specific antigens that could serve as targets for the autoimmune responses in APS • it has been suggested that an APS may be due to external agents sharing one or more epitopes with a common antigen in several endocrine tissues Autoimmune polyendocrine syndrome type 1 (APS-1)
    • pathogenesis • It has been hypothesized that mutations of the AIRE gene cause loss of peripheral antigen expression in the thymus and probably decreased deletion of autoreactive T lymphocytes that target such peripheral antigens. Autoimmune polyendocrine syndrome type 1 (APS-1) De martinilo :APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors. Front immunology. 2013 Oct 23;4:331. eCollection 2013.
    • pathogenesis • AIRE gene function : expression of tissue specific antigen (self-antigin) to thymocytes • which lead to self tolerance by elimination of the autoreactive T cells. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • T T-cell precursor or developing T-cell A Auto reactive, self-reactive, pathological T-cell (CD4+ or CD8+) Rn Ri Natural regulatory T-cell or suppressor induced regulatory T-cell or suppressor mTEC Medullary thymic epithelial cell APC Antigen presenting cell Antigen CD 4 H CD4+ helper cell (CD4+,CD25+, FOXP3)R
    • THYMUS CENTRAL TOLERANCE T T-cell precursor negative Selection (apoptosis) T mTEC + AIRE A A APC + AIREA anergy Ignorance Ri Ri A A A A A A PERIPHERY Rn Rn Rn positive selection A Rn Rn Rn Rn Rn Rn CD 4 H CD4+ and CD8+ TCD4+ or CD8+ TEC
    • Diagnosis of APS-1 • Clinical diagnosis requires the presence of two from three major criteria (Whitaker’s triad) : • 1-mucocutaneous candidiasis. • 2-Hypoparathyroidism. • 3- Adrenocortical insufficiency (or autoantibodies against 21 hydroxylase) • or If a sibling has the syndrome only one major is required • diagnosis could be made by molecular genetics in presence of minors. Proust- lemoine E. Polyglandular autoimmune syndrome type I. Presse Med .2012 Dec;41(12 P 2):e651-62. doi: 10.1016/j.lpm.2012.10.005. Epub 2012 Nov 23. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • • Different genotype lead to different phenotypes. • Different genotype can lead to same phenotype. (overlaping) • One genotype can lead to different phenotypes presentation Autoimmune polyendocrine syndrome type 1 (APS-1)
    • presentation • Patients begin with CMC, followed by hypoparathyrodism and finally by addison. • It has been observed that the earlier was the first clinical presentation, greater will be the number of diseases that will develop during the life of a patient with APS-1 Sarinda Millar, Dennis Carson. Clinical phenotypes of autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy seen in the Northern Ireland paediatric population over the last 30 years. Ulster Med J 2012;81(3):118-122 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Chronic mucocutaneous candidiasis CMC • is often the first condition detected . • The onset is usually before 5 years of age . • the first sign of APS I in 60% patients. • by 40 years of age 100% of patient with APS will developed candidiasis . Autoimmune polyendocrine syndrome type 1 (APS-1)
    • CMC • the etiology :due to a selective immunological deficiency of T cells towards Candida albicans. • Humoral immunity B-cell function normal. • Anticytokines autoantibodies against the Th17- related cytokines (IL-22,IL-17A and IL-17F) were implicated . Sarinda Millar, Dennis Carson. Clinical phenotypes of autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy seen in the Northern Ireland paediatric population over the last 30 years. Ulster Med J 2012;81(3):118-122 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • • Presentation: • Oral candidiasis (thrush) • Diaper rash. • vulvovaginal candidiasis at puberty in females. • Nail infection :leading to a darkened discoloration, thickening, or erosion. • intestinal mucosal candidiasis :lead to intermittent abdominal pain and diarrhea. Chronic mucocutaneous candidiasis CMC Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Chronic mucocutaneous candidiasis CMC • Retrosternal pain occurring in patients with confirmed oral candidiasis suggests esophageal candidiasis which may lead to stricture and dysphagia. • epithelial carcinoma of the oral mucosa, tongue or esophagus with its high mortality is well described in APS I patients with chronic mucosal candidiasis. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Chronic hypoparathyroidism • usually presents before puberty. • Pathology: • an atrophy and infiltration of the parathyroid glands with mononuclear cells. • clinically patient may present with paresthesias, hypereccitability, hypotension, carbopedal spasim , laryngospasm and generalized seizures. • These symptoms may, however, be masked in the presence of adrenal insufficiency. • Papilledema and calcification of the basal ganglia are other signs of chronic hypocalcaemia. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Chronic hypoparathyroidism • hypocalcemia ,Hyperphosphatemia with a low parathyroid hormone(PTH) level is diagnostic. • Recently, in patients with APS-1 and hypoparathyrodisim, autoantibodies against calcium- sensing receptors and other autoantibodies have been reported • Antibodies aginest NALP5 have been found in 49% of patient with APS-1. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Addison disease • is found in more than 85% of APS I • adrenocortical failure usually has its peak onset before adolescence. • Pathology: • showed atrophy of the glands and lymphocyte infiltration • Deficiencies of cortisol, aldosterone, and adrenal andogens may present simultaneously or may evolve over months to several years. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Addison disease • Clinical Presentation • The initial clinical features are often non specific • These include fatigue, weight loss, myalgias, arthralgias, behavioral changes, nausea and vomiting, abdominal pain, weight loss and diarrhea. • Hyperpigmentation and postural hypotension • Adrenal crises with hyponatremia, hyperkalemia, and hypoglycemia . Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Other associated diseases (Minor) Mohammed Al-Owain :Renal Failure Associated with APECED and Terminal 4q Deletion:Evidence of Autoimmune Nephropathy Case Report. Clinical and Developmental Immunology Volume 2010, Article ID 586342, 7 pages watanbe M .Myopathy in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Uscle nerve. 2012 Jun;45(6):904-8. hyposplenism or asplenia.Gonadal failure. policlonal hypergammaglobulinemiaautoimmune thyroiditis. IgA deficiency.autoimmune hepatitis. Vasculitis.type 1 diabetes. sublenticular cataract.Cholelithiasis. calcification of basal ganglia.Atrophic gastritis. tympanic membranes calcification.Malabsorption. rheumatoid arthritisDental enamel hypoplasia. pure red cell aplasia.Vitiligo. Cerebellar Degeneration.Alopecia. KeratoconjunctivitisPericarditis. Sjögren’s syndrome.Pernicious anemia. Polyneuropathy.pulmonary disease. Myopathy*IDA Autoimmune Nephropathy*Encephalopathy. (APS-1)
    • gonadal failure (Hypergonadotropic hypogonadism) • more common in females. • 50% of women with APS I develop ovarian failure by 20 years of age. • In most cases presents usually as secondary amenorrhoea although in some cases as primary Amenorrhoea • Also menstrual irregularities, polycystic ovaries, or infertility • Less than 30% of men with APS I develop testicular failure. • In 60-80% of patients with APS-1, steroid-producing cell antibodies (StCA) have been detected . Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Autoimmune thyroid diseases • Autoimmune thyroid diseases (ATD) occur in 4- 36% of cases . • between 9-32 years of age and usually as chronic thyroiditis • Anti-microsomial (anti-peroxidase) and/or anti- thyroglobulin antibodies are detected in most patients with autoimmune thyroid diseases Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Autoimmune hepatitis • Autoimmune Hepatitis occurs in 10% to 31% of APS I. • Subclinical to fulminant hepatic failure. • the leading cause of death in these patients. • all patients suspected of having APS I should have their liver function regularly monitored. • Autoimmune hepatitis in APS-1 correlates with positive antibodies against liver and kidney microsomes (anti- LKM) • Anti-LKM antibodies are present even in 25% without alterations in their liver function tests. Autoimmune polyendocrine syndrome type 1 (APS-1) Bialkosowska J: Hepatitis and the polyglandular autoimmune syndrome, type 1. Aech med sci . 2011 Jun;7(3):536-9. doi: 10.5114/aoms.2011.23427. Epub 2011 Jul 11.
    • malapsorption • Many ossotiated condition implicated including: • Coeliac disease ,cystic fibrosis, pancreatic insufficiency ,intestinal infections from Candida Albicans, intestinal lymphangectasia , idiopathic cholecystokinin deficiency • In some patients cause unknown “idiopathic malabsorption” • in 48% of patients with APS-1 the tryptophan hydroxylase autoantibodies were detected. • TPH-Abs are absent in patients with gastrointestinaldisorders but unaffected by APS-1 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Management Autoimmune polyendocrine syndrome type 1 (APS-1) Specific organ autoantibody screening assessment of endocrine function Genetic study + general antibodies
    • screening • In hypothyroid patients with confirmed APS, evidence for adrenal autoimmunity must also be sought before starting thyroid hormone replacement therapy • Usually, sudden hypercalcemia in hypoparathyroid individuals may signal the beginning of adrenal insufficiency Autoimmune polyendocrine syndrome type 1 (APS-1)
    • screening • Any patients with APS-1 should be seen and screen for autoantibodies at 6-month intervals. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Meloni A, Furcas Met al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008;93:4389–97 • Studies showed that upto 100% of patients with APS-1 have been found to express autoantibodies reacting with interferon-omega . • also the great majority express autoantibodies reacting with interferon alpha. • their role in pathogenesis still controversy. PathogenesisAutoimmune polyendocrine syndrome type 1 (APS-1) (Anti-IFN-ω and Anti-IFN-α)
    • jaaskelainen j ,Perheentupa Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)--a diagnostic and therapeutic challenge. endocrinology review 2009 Dec;7(2):15-28. • search for autoantibodies against interferon-omega, enables proof or exclusion of APECED with more certainty than gene analysis. • It is highly specific and sensitive for APECED if thymoma and myasthenia gravis are excluded • Its present early in course of the disease and persist for years Autoimmune polyendocrine syndrome type 1 (APS-1)
    • screening • Any patient with suspected APS should be screened with a panel of autoantibodies : • type I interferons autoantibodies (α and ω) • adrenal cortex cytoplasmic autoantibodies. • 21 hydroxylase autoantibodies. • GADA, IA-2A, IAA,ZnT8 andICA • thyroid microsomal/thyroperoxidase autoantibodies. • thyroglobulin autoantibodies. • steroidal cell autoantibodies. • P450 1A2 and AADC autoantibodies • Anti-LKM antibodies. • endomysial or transglutaminase autoantibodies. • Internisic factor. • H+ K+ ATPase autoantibodies. • Parital cell autoantibodies. • Autoantibodies against tyrosine hydroxylase • Complement-fixing melanocyte antibodies
    • Assessment of end-organ function • Assessment of end-organ function in any patient with autoantibodies is recommended annually. Investigation early morning cortisol levels electrolyte :sodium, potassium renins Fasting blood glucose testing calcium, phosphate, and PTH TSH level,FT4 Investigation FSH and LH levels Testesteron , estradiol hemoglobin and hematocrit mean corpuscular volume vitamin B12 level Liver function tests Autoimmune polyendocrine syndrome type 1 (APS-1)
    • Treatment of APS-1 • will depend upon the autoimmune disorder identified . • Candidiasis: antifungal. • aggressive therapy of oral is indicated in order to prevent the late complication of epithelial carcinoma. • Fluconazole is preferred over ketconazole. • Hypoparathyrodisim: calcium and one alph. • Addision : hydrocortison or prednisolone + fludrocortisone. • Type 1 DM: insulin. Autoimmune polyendocrine syndrome type 1 (APS-1)
    • • Hypothyrodisim: levothyroxine. • Hypergonadotropic hypogonadism: testosterone in male, estrogen and progestrone in female. • asplenia :vaccinations and prophylactic antibiotic. • Autoimmune hepatitis : immunosuppresent. • Keratoconjunctivitis : immunosuppresent. • Malabsorption : immunosuppresent. • pure red cell aplasia : immunosuppresent. Treatment of APS-1 Autoimmune polyendocrine syndrome type 1 (APS-1)
    • • APS-2 is the most common autoimmune polyendocrine syndrome. • incidence of 1:20 000 • more common in females than in males. • onset in adulthood. • particularly during the third or fourth decades. Dtsch Med Wochenschr. 2013 Feb;138(7):319-26; quiz 327-8. doi: 10.1055/s-0032-1327355. Epub 2013 Feb 7.[Autoimmune polyglandular syndromes]. Autoimmune polyendocrine syndrome type 2 (APS-2)
    • pathogenesis of APS II • the precise aetiology is unknown. • cases occur sporadically or within families. • inheritance of PAS II is complex. • Within some families, it appears to be inherited as an autosomal dominant. • genes on chromosome 6 playing a predominant role. this chromosome contains the major histocompatibility loci. George J Kahaly. Polyglandular autoimmune syndromes. European Journal of Endocrinology (2009) 161 11–20 Autoimmune polyendocrine syndrome type 2 (APS-2)
    • pathogenesis • patients with APS II have HLA associations similar to those of patients with type 1 diabetes.. • The primary association of APS-2, appears to be with class II HLA alleles with DR3/DQ2 and DR4/DQ8 • Primary adrenal insufficiency in type 2, but not in type 1 APS, is strongly associated with both HLADR3 and HLA-DR4 Autoimmune polyendocrine syndrome type 2 (APS-2)
    • Diagnosis of APS II • is defined by the coexistence of : • Autoimmune adrenocortical insufficiency or serologic evidence of adrenalitis with one or more of the following : • 1- autoimmune thyroiditis or serologic evidence of thyroid autoimmunity. • 2- type 1 diabetes mellitus or islet autoimmunity. • (Schmidt syndrome) : adrenocortical insufficiency + autoimmune thyroiditis • (Carpenter syndrome) Schmidt syndrome + type 1 diabetes Autoimmune polyendocrine syndrome type 2 (APS-2)
    • Presentation • Adrenocortical failure is the intial presentation in approximately 50% of APS II cases. • autoimmune thyroid disease (AITD) coexists in 80– 90% of females with Addison disease. • Type 1 diabetes coexists in nearly 50% of patients with Addison disease. Autoimmune polyendocrine syndrome type 2 (APS-2) Ali Y: Polyglandular autoimmune syndrome type 2: diagnosed in the intensive care unit. Ther Adv Endocrinol Metab. 2013 Dec;4(6):170-2. doi: 10.1177/2042018813515698.
    • • Vitiligo. • autoimmune lymphocytic gastritis. • Alopecia. • Gonadal failure. • Hypophysitis. • empty sella syndrome. • ulcerative colitis. • primary biliary cirrhosis. • Sarcoidosis. • Achalasia. • neuropathy. • Thrombocytopenic purpura • IgA deficiency. • juvenile dermatomyositis • dermatitis herpetiformis, • scleroderma, Other associated diseases Autoimmune polyendocrine syndrome type 2 (APS-2)
    • Other APS • IPEX. • Thymic tumor disease. • POEMS syndrome. • Hirata syndrome. • Adult combined pitutary hormone deficincy(CPHD). • Kearn-sayre syndrome. • DIDMOAD syndrome.
    • IPEX • IPEX (immune dysfunction, polyendocrinopathy, and enteropathy, X-linked). • also called XLAAD (X-linked autoimmunity and allergic dysregulation) • fatal autoimmune lymphoproliferative disease. • rare X-linked recessive. • Due to the absence of normal FoxP3 expression • Neonatal onset type 1 diabetes,dermatitis, enteropathy, thyroiditis, hemolytic anemia, and thrombocytopenia. • long-term immunosuppression or bone marrow transplantation appears to be the only effective therapy for IPEX.
    • ‫رب‬ ‫يا‬ ‫األطفال‬ ‫ضحكة‬ ‫وصن‬‫انها‬ ‫إذا‬‫غردت‬ ‫ما‬‫الرمل‬ ‫موحش‬ ‫في‬‫اعشبا‬